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Glycoengineered Outer Membrane
Vesicles: A Novel Platform for
Bacterial Vaccines
Nancy L. Price1, Guillaume Goyette-Desjardins2, Harald Nothaft1, Ezequiel Valguarnera3,
Christine M. Szymanski1, Mariela Segura2 & Mario F. Feldman1,3
The World Health Organization has indicated that we are entering into a post-antibiotic era in which
infections that were routinely and successfully treated with antibiotics can now be lethal due to the
global dissemination of multidrug resistant strains. Conjugate vaccines are an effective way to create a
long-lasting immune response against bacteria. However, these vaccines present many drawbacks such
as slow development, high price, and batch-to-batch inconsistencies. Alternate approaches for vaccine
development are urgently needed. Here we present a new vaccine consisting of glycoengineered outer
membrane vesicles (geOMVs). This platform exploits the fact that the initial steps in the biosynthesis of
most bacterial glycans are similar. Therefore, it is possible to easily engineer non-pathogenic Escherichia
coli lab strains to produce geOMVs displaying the glycan of the pathogen of interest. In this work we
demonstrate the versatility of this platform by showing the efficacy of geOMVs as vaccines against
Streptococcus pneumoniae in mice, and against Campylobacter jejuni in chicken. This cost-effective
platform could be employed to generate vaccines to prevent infections caused by a wide variety of
microbial agents in human and animals.
Most successful current antibacterial vaccines are glycoconjugates, composed of cell surface carbohydrates
chemically attached to an appropriate carrier protein. These are effective means to generate protective immune
responses to prevent a wide range of diseases. One of the best examples is the conjugate vaccine against
Haemophilus influenzae type b, which practically eliminated the disease caused by this bacterium in vast parts
of the world. Other examples are the vaccines against Streptococcus pneumoniae and Neisseria meningitidis, both
based on capsular polysaccharides1,2. However, the current technology to produce conjugate vaccines presents
some drawbacks3–5. These require complex synthetic chemistry for obtaining, activating, and attaching the
polysaccharides to protein carriers. The carbohydrates employed for the formulation of these vaccines are usually
obtained from pathogenic organisms, which may constitute a hazard and may require higher levels of biosafety
for production. Some of the glycans containing acid-labile sugars do not resist the chemical treatment required
for their purification and crosslinking to proteins. Furthermore, the chemical crosslinking is often not reproducible, resulting in unreliable products with batch to batch variability. Novel approaches are needed to effectively
prevent bacterial infections, especially in the context of the alarming increase of MDR bacterial strains.
Gram-negative bacteria are able to produce outer membrane vesicles (OMVs). OMVs are mainly composed of LPS, outer membrane and periplasmic proteins, and phospholipids6. OMVs are formed by blebbing
of the outer membrane, although their biogenesis is poorly understood7. Due to their immunogenic properties,
self-adjuvanticity, ability to be taken up by mammalian cells, and capacity for enhancement by recombinant
engineering, OMVs are attractive candidates for vaccine delivery platform8. Within the last 25 years, vesicle
based meningococcal vaccines (i.e., MenBvac , MeNZB , and BexSero ) have been successfully developed and
employed within various countries9–16. Due to their success, other OMV vaccine candidates for various pathogenic bacteria including Vibrio cholerae17,18, Bordetella pertussis19, Burkholderia pseudomallei20,21, Acinetobacter
baumannii22 and even Gram-positive bacteria, such as Bacillus anthracis23, have been tested. Such OMV based
vaccines involve direct manipulations of large volumes of pathogenic bacteria and may pack unwanted bacterial
toxins.
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Figure 1. The geOMV platform. Genetic locus encoding glycan structure of interest is cloned into expression
vector and introduced into an engineered E. coli strain which generates vesicles that display the glycan. The
collected geOMVs can be directly utilized for immunizations.
Pneumococcal disease kills more patients worldwide than any other vaccine-preventable disease. Annual
worldwide statistics show that 1.6 million people die of pneumococcal disease24. The current vaccine (Prevnar
13 ) protects against the 13 predominant serotypes in the USA, but serotypes that are important in other countries are not included in the vaccine. Furthermore, serotypes with lower prevalence often take over the niche left
by the serotypes included in the vaccines25. Therefore effective vaccines for the remaining S. pneumoniae capsule
serotypes are needed. Campylobacter jejuni is a natural commensal in all birds, including chickens. Humans
are frequently infected with C. jejuni through the consumption of improperly cooked poultry. In most cases,
infection only causes diarrhea, fever and abdominal pain. However, approximately, one in one thousand patients
will develop a severe polyneuropathy known as Guillain-Barré syndrome (GBS)26. One way to control human
infection by C. jejuni would be to reduce the load of the bacterium in chickens. Here we present an alternative
platform for vaccines consisting of glycoengineered OMVs (geOMVs) derived from non-pathogenic engineered
Escherichia coli strains expressing bacterial surface glycans encoded by the bacterial pathogenic organisms. As
a proof of principle, we demonstrate the efficacy of geOMVs as vaccines for S. pneumoniae serotype 14, and the
common foodborne pathogen C. jejuni.

®

Results

Generation of geOMV displaying S. pneumoniae serotype 14 capsule (CPS14). The general strat-

egy for the production of geOMV is represented in Fig. 1. In principle, our platform can be applied to any surface
glycan, such as O antigens, capsules, exopolysaccharides, or glycans present in N- and O-glycoproteins. The initial
steps in the biosynthesis of these glycans are common. These include the assembly of the glycan onto the undecaprenylpyrophosphate carrier and the flipping of the lipid-linked sugars across the inner membrane of Gramnegative or the cell membrane in Gram-positive bacteria. If these pathways are reconstituted in E. coli, the WaaL
ligase transfers the glycan from the carrier to the lipid A, which is synthesized independently, and exported to
the bacterial surface. OMVs displaying such antigens are then naturally produced. The biosynthetic pathways of
type I capsular polysaccharides and O antigens only diverge once the polysaccharide has been translocated across
the inner membrane (Supplementary Data, Fig. S1a). WaaL is not glycan-specific and can transfer a variety of
sugars onto the lipid A core27. We predicted that expressing the S. pneumoniae capsule in an E. coli strain lacking
its own O antigen would result in an LPS consisting of capsular polysaccharide attached to the lipid A core. To
obtain such a strain, we constructed an inducible plasmid (pNLP80) which expresses the capsule synthesis cps
locus and includes all essential glycosyltransferases, the flippase (Wzx), and the polymerase (Wzy) required for
the synthesis of the S. pneumoniae serotype 14 capsule (CPS14). The expression of CPS14 was evaluated in two
different E. coli mutant strains, CLM3728 and CLM2429 (Fig. 2a). CLM37 harbours a mutation which interrupts
the initiator glycosyltransferase (wecA) for O antigen and Enterobacterial common antigen (ECA) synthesis28.
In Streptococcus capsule synthesis the initiating glycosyltransferase is WchA, which transfers a glucose residue
to the Und-PP carrier. WecA and WchA attach different sugars to the lipid and therefore would compete for the
carrier. We reasoned that a wecA mutant strain, such as CLM37, in which competition for Und-PP is minimized,
should produce more CPS14 than the wild-type strain. To demonstrate the attachment of the CPS14 to lipid A,
we employed strain CLM24 (waaL mutant)29. In this strain the glycan remains attached to the lipid carrier and
CPS14 should not be transferred to the lipid A. LPS extractions and OMV obtained from the two E. coli mutants
show the presence of CPS14 in the WecA mutant but not in the WaaL ligase mutant strain, which indicates that
CPS14 is attached to the lipid A core and directed to the vesicles in strains such as CLM37 that carry an intact
WaaL (Fig. 2a). The signal detected in the WaaL mutant strain corresponds to UndPP-linked CPS14. The geOMVs
were visualized by transmission electron microscopy (TEM) (Fig. 2b).
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Figure 2. The S. pneumoniae serotype 14 capsule can be produced in E. coli. (a) Western blot analysis of
CPS14 expressed in E. coli strains CLM37 (wecA-; waaL+) and CLM24 (wecA+; waaL-) show the production
of the pneumococcal capsule in whole cell lysates, LPS extractions, and isolated OMVs. (b) TEM of isolated
pneumococcal geOMVs.

Figure 3. Sera from mice injected with geOMVs displaying S. pneumoniae serotype 14 capsule antigens
cross react with the S. pneumoniae capsule. (a) Western blots of geOMVs from CLM37 strain with vector
control (VC) or S. pneumoniae serotype 14 capsule (CPS14). The S. pneumoniae serotype 14 capsule was
visualized by either the commercially available rabbit anti-capsule serotype 14 antibody (red) and the mice
sera (green). The overlapping signals are shown in yellow (merged). (b) Pneumococcal geOMVs display the
similar immunogenic response as the commercial available Prevnar 13 pneumococcal vaccine. Mice sera
(n =  10) collected at day 42 were incubated in wells of ELISA plates seeded with whole cell S. pneumoniae
serotype 14. Figure shows statistically significant differences between means for each group. (*p-value <  0.0001;
**p-value <  0.0001; NS p-value 0.0298). Error bars are SD and P values were calculated using the unpaired
t-test.

geOMV displaying S. pneumoniae CPS14 raise specific antibodies and are effective in OPA
assays. To determine whether geOMVs from CLM37 strain displaying the CPS14 would generate an immu-

nogenic response in a murine model, we injected 2 μ g of geOMVs per mouse (n =  10). Control groups immunized with either geOMVs lacking the capsule (empty geOMVs) or the commercially available Prevnar 13 , were
included for comparison. Booster doses of geOMVs and Prevnar were administered on Days 14 and 28 and
sera was collected weekly over a 42 day period. Collected sera of the immunized mice were assayed via Western
blot analysis (Fig. 3a). Initial immunization with geOMVs did not elicit an IgG immunogenic response. However
one week after the first booster dose (Day 21), high IgG titers in response to CPS14 were generated (Fig. 3a). The
IgG response continued to be observed over the remaining course of the immunization schedule. To determine
whether the immunogenic response was specific for serotype 14, we performed ELISAs with whole pneumococcal
cells of serotypes 14 and 9 V (Supplementary Data, Fig. S1b,c). Sera from mice injected with geOMVs with CPS14
reacted only with S. pneumoniae serotype 14, thus demonstrating that the immunogenic response is specific
for the glycoengineered serotype. Furthermore, at day 42, the levels of the IgG response of mice injected with
pneumococcal geOMVs were comparable to the immunogenic response of mice injected with the commercially
marketed pneumococcal vaccine Prevnar 13 (Fig. 3b) which suggested that the level of the protective effect
could also be similar.
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Figure 4. Bactericidal activity of sera from vaccinated mice against S. pneumoniae serotype 14.
(a) Opsonophagocytosis assay (OPA) evaluation of the effect of the incubation time (2 h and 4 h) on
S. pneumoniae type 14 killing in presence of either 20% (v/v) placebo or vaccinated mice sera. Statistically
significant differences were found at 2 hours and at 4 hours between the placebo and the vaccinated mice sera
(*p-value <  0.0001; **p-value <  0.0001). Plotted data are means of percentages and SD as error bars. KruskalWallis (non-parametric) test was used to calculate p-values. (b) OPA evaluation of the effect of the serum
concentration (5% and 20%) on S. pneumoniae type 14 killing at 4 h incubation in presence of sera from mice
vaccinated with either a pneumococcal geOMVs or Prevnar 13 commercial vaccine, used for comparative
purposes. Commercial rabbit anti-S. pneumoniae type 14 serum was used as positive control to validate OPA
methodology. No statistically significant differences could be observed between different serum concentrations
(NS1 p-value =  0.15; NS2 p-value =  0.21). P-values were calculated using Kruskal-Wallis test. No bacteria were
found when using 20% serum concentration.

Opsonophagocytosis assays (OPA) are accepted as one the most reliable ways to evaluate the efficacy of pneumococcal vaccines30. OPA were performed to evaluate the efficacy of geOMVs against an S. pneumoniae serotype
14 infection. Day 42 sera obtained from the three groups of immunized mice (i.e., placebo geOMVs, pneumococcal geOMVs, and Prevnar 13 ) were employed. OPA showed a significantly increased killing effect using
pneumococcal geOMVs compared to placebo geOMVs (Fig. 4a), which suggests that isolated pneumococcal
geOMVs elicit a protective effect in vitro. In addition, varying mouse serum concentrations (5% and 20%) showed
a similar killing effect between pneumococcal geOMVs and the Prevnar 13 pneumococcal vaccine (Fig. 4b),
thus demonstrating that geOMVs have a similar protective effect when compared to the commercially available
Prevnar 13 vaccine.

®

®

geOMV reduce chicken colonization by C. jejuni.

We next evaluated the use of geOMVs to vaccinate
chickens against C. jejuni. We introduced a plasmid (pACYCpglBmut) that expresses the C. jejuni heptasaccharide N-glycan into E. coli EVV11. This strain carries a mutation in Wzy and therefore does not polymerize
the C. jejuni glycan as the wild-type strain does. We isolated geOMVs from this strain and analyzed them by
Western-blot employing an N-glycan specific antibody. An immunoreactive signal migrating around 15 kDa that
was absent in control OMVs clearly indicates that the C. jejuni N-glycan was displayed in geOMVs (Fig. 5a). To
analyze the efficacy of the geOMVs containing the C. jejuni N-glycan, we tested the protective effect of these
geOMVs in a C. jejuni chicken challenge model. Four groups of chickens (n =  8 for the positive control, n =  6
for the negative and experimental groups) were vaccinated orally with PBS, placebo geOMVs or Campylobacter
geOMVs, and challenged with oral doses of PBS (negative control) or C. jejuni strain 81–176. Birds were monitored for 7 days before being euthanized and the amount of C. jejuni isolated from the cecum was determined for
each bird. Birds that received PBS (Fig. 5b, group 2) and placebo geOMVs (Fig. 5b, group 3) showed similar levels
of C. jejuni colonization after challenge. Chickens vaccinated with the N-glycan-containing geOMVs exhibited
an almost 104-fold reduction in C. jejuni colonization after challenge when compared to the naïve and placebo
groups (Fig. 5b, group 4). In agreement with this data, the IgY levels of chicken that received the geOMV containing the glycan were higher than the ones that received the empty OMV (Fig. S1d).

Discussion

Conjugate vaccines are an effective way to create a long-lasting IgG immune response. However, besides being
expensive to produce, these vaccines present a series of drawbacks. Large volumes of pathogenic cells need to be
cultured to obtain the polysaccharides and the chemical crosslinking of the sugars to the protein is complex, with
large batch to batch variability. The development of novel conjugate vaccines is very slow. Diverse serotypes not
included in Prevnar 13 are prevalently being isolated in different geographical locations, and therefore novel
technologies that can accelerate the development of multivalent vaccines are required. The generation of conjugate vaccines through exploitation of bacterial protein glycosylation systems is a very promising alternative, but
not all the glycan chains are efficiently attached to proteins by the oligosaccharyltransferase PglB, which requires
a HexNAc residue at the reducing end of the sugar chain31. PglL, the N. meningitidis O-oligosaccharyltransferase,
can recognize a galactose but not glucose residue at the reducing end (Feldman, manuscript in preparation).
Interestingly, about 90% of the S. pneumoniae strains contain glucose at the reducing end. Here we demonstrated
that OMVs produced by glycoengineered E. coli expressing a glycan from unrelated bacterial pathogens, such as
the CPS14 capsule from S. pneumoniae or the heptasaccharide derived from N-liked glycans from C. jejuni, can
be effective in producing a significant immune response.
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Figure 5. geOMVs displaying the N-heptasaccharide reduce C. jejuni colonization in chicken. (a) Western
blots of E. coli EVV11 geOMVs displaying no oligosaccharides (lane 1) and the heptasaccharide N-glycan
(lane 2). (b) Campylobacter colonization in chicken. Group 1, non-vaccinated, not challenged (background
control); group 2, non-vaccinated, challenged (colonization control); group 3, vaccinated with empty OMVs
and challenged; group 4, vaccinated with geOMVs expressing the N-glycan and challenged. Each data point
represents cfu/gram cecal content for one bird. The median for each group is represented by a black bar. No
significant difference in colonization could be observed between groups 2 and group 3 (NS p-value =  0.29).
A statistically significant reduction in colonization was observed in group 4 birds that received the Cj-N-glycan
presenting OMVs when compared to either group 3 (*p-value =  0.045) or group 2 (**p-value =  0.032). No
Campylobacter cells were detected in group 1, the detection limit based on the experimental setup was 200 cfu/gram
cecal content. P-values were calculated by the one-way ANOVA test.

In the case of S. pneumoniae, geOMVs induced an immune response, as measured by serum IgG levels
and efficacy in OPA tests, which was similar to the one generated by the most widely used commercial
conjugate vaccine. In the future, a multivalent vaccine could be generated by mixing geOMVs carrying
capsules from different serotypes. Furthermore, geOMVs could complement the current conjugate vaccines,
especially for serotypes corresponding to glycan structures for which the conjugation has not been solved.
Although the Western blots together with the specific antibody response to CPS14 and the OPA assays suggest that the right structure of the CPS14 has been displayed in the geOMVs, future work will confirm the
exact structure attached to lipid A. In the case of the C. jejuni geOMV vaccine candidate, the 4 log reduction
in chicken colonization is, to our knowledge, unprecedented for this microorganism. However, the power of
the vaccine could be increased if, in addition to engineering E. coli to produce pathogenic bacterial surface
glycans, the geOMVs were modified to express antigenic membrane proteins to be directed to the vesicles.
Previous studies have already explored incorporating antigenic proteins from pathogenic species (Neisseria,
Streptococcus, Leishmania, Vibrio, and Yersinia) into vesicles derived from laboratory E. coli and Salmonella
strains17,32–35. Furthermore, OMV produced in Salmonella carrying pneumococcal protein antigens showed
promise in murine models36. The geOMV platform would enable the glycans and proteins to synergistically
increase the vaccine immunogenicity capacity. This can also be important for cases like in S. pneumoniae, in
which a protein antigen could expand the protection to serotypes not included in the vaccines.
One of the main concerns with vesicle based vaccines is the safety issues as OMVs contain endotoxic LPS37.
LPS lipid A has been shown to provoke severe/lethal inflammatory responses in the host38–40. The OMV vaccines employed in humans were derived from Neisseria meningitidis. Several studies have analyzed the effect
of modifying the lipid A to abrogate its interactions to obtain OMVs with LPS preparations tailored for human
vaccine development41–43. For example, N. meningitidis strains lacking LpxM or LpxL also render a lipid A with
minimal toxicity41,44. It has been shown that OMVs produced in E. coli can also be detoxified through modifications of the lipid A37. These modifications can be carried out through the action of lipid A deacylases, such as
PagL45. The overexpression of B. pertussis PagL resulted in OMVs with lower endotoxic activity compared to
wild type B. pertussis OMVs. Monophosphorylated lipid A species recently became the first new Food and Drug
Administration-approved adjuvant in several decades46. Therefore, it might be possible to generate geOMVs with
a perfect balance between reduced toxicity and optimal adjuvanticity by generating strains containing modifications in the levels of lipid A acylation, phosphorylation, and/or other modifications.
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Material and Methods

Animal ethics statement. All experiments involving mice were conducted in accordance with the guidelines and policies of the Canadian Council on Animal Care and the principles set forth in the Guide for the Care
and Use of Laboratory Animals. The animal protocol was approved by the Animal Welfare Committee of the
University of Montreal (protocol #RECH-1523). Studies involving chickens were carried out in accordance with
the protocol approved by the Animal Care and Use Committee at the University of Alberta using a 35 day challenge protocol.
Construction of pneumococcal glycan expression plasmid. The cps gene cluster responsible for the synthesis of S. pneumoniae capsule serotype 14, CPS14, (excluding the regulatory genes) was
cloned via a 3-way ligation method. Two separate fragments of the CPS14 locus were amplified using a
high fidelity polymerase (iProof , BioRad). Fragment 1 amplified the wchA-wchM region using the forward primer
(5′-ATAGAGCTCATGGATAAAAAAGGATTGGAAAT-3′) and reverse primer (5′-TTAAGAAATTCATCCT
CATACAA-3′). Fragment 2 amplified the wchM-wciY region using the forward primer (5′-CTGGTCAAC
AAATATTAGAAAAA-3′) and reverse primer (5′ATACTCGAGATTCTTTCTGTAAACTCCAAAAA-3′). The
underlined sequences denotes SacI and XhoI restriction enzyme sites, respectively. The PCR fragments 1 and 2
were both designed to include the native HindIII site within the wchM gene, thus, after a HindIII RE digest, the
two fragments were compatible and reconstituted the wchM gene after ligation. Both fragments were successfully
amplified and digested with SacI/HindIII (fragment 1) or HindIII/XhoI (fragment 2) and cloned into the plasmid
vector pBBR1MCS-2, which was double digested with SacI and XhoI, generating pBBR1MCS-CPS14. The cloned
CPS14 locus was confirmed by restriction enzyme digests and sequencing. For proper expression of the CPS14
locus in E. coli, the CPS14 locus was subcloned into pWSK129. The wchA-wciY CPS14 fragment was cleaved
from pBBR1MCS-CPS14 using SacI and XhoI restriction enzymes. pWSK129 was digested with SacI and SalI
restriction enzymes. As XhoI and SalI generate compatible sticky ends, the wchA-wciY fragment was ligated into
pWSK129. The resulting plasmid, named pNLP80 was introduced in E. coli strains.

™

Isolation of geOMVs from E. coli expressing bacterial glycans. geOMVs were isolated following
the protocol described by Haurat et al.47. Briefly, E. coli strains harbouring plasmids expressing genes involved in
glycan synthesis (i.e., pNLP80, pEQ3, pACYCpglBmut) and the respective vector control plasmids were grown at
37 °C overnight with shaking in 50 mL of Luria-Bertani (LB) broth plus appropriate antibiotics. The following day,
each culture was subcultured (1:100 dilution) into 1 L LB or Terrific Broth (TB) plus antibiotics and grown at 37 °C
with shaking for 2 h (OD600 ~ 0.2). Inductions of glycans were performed as follows: IPTG was added to a final
concentration of 0.1 mM to induce expression of Streptococcus CPS14 (pNLP80) while the Campylobacter heptasaccharide biosynthetic gene cluster on pACYCpglBmut is constitutively expressed. The cultures were grown for
an additional 26 h at 37 °C with shaking. After incubation, cells were harvested by centrifugation at 23,000 ×  g
for 15 min and the supernatant was collected. The supernantants were filtered twice through 0.44 μ m and 0.2 μ m
filters to remove any residual intact cells. The filtered supernatants were ultracentrifuged at 210,000 ×  g for 3 h at
4 °C. The geOMV pellets were collected and resuspended in buffered saline (PBS).
Analysis and quantification of geOMV. Presence of geOMVs containing Streptococcus CPS14 or
Campylobacter heptasaccharide was confirmed by Western blotting. Quantification of geOMVs was performed by
measurement of KDO using a modified protocol described by Lee and Tasi48. Commercially available anti-rabbit
CPS14 antibody (Statens Serum Institut, Denmark) was used as positive control (1:1000 dilution) to visualize the
presence of the pneumococcal capsule.
Transmission electron microscopy. Isolated geOMVs were absorbed onto carbon-coated copper membrane grids
for 3 min. Excess geOMVs were blotted away from membrane grid and samples were negatively stained with 2%
(w/v) uranyl acetate (3 min). The grids were analyzed for presence of geOMVs using a Morgagni (FEI) transmission electron microscope (Biological Sciences Microscopy Facility, University of Alberta).
Murine studies with Pneumococcal geOMVs. Three groups of BALB/c mice (n =  10 per group, female, 4–6 weeks
old, obtained from Charles River, WA) were immunized intraperitoneally. The test group was injected with 2 μ g
of geOMVs isolated from E. coli CLM37 strain expressing CPS14 (pNLP80). A placebo control group received
geOMVs isolated from E. coli CLM37 strain not expressing CPS14. The third group was injected with commercially available dose of Prevnar 13 (500 μ L as supplied). Sera were collected weekly via tail bleeds over a 42 day
period and booster doses were administered on Days 14 and 28. Final bleed (Day 42) was via cardiac puncture.
The presence of antibodies against CPS14 was analyzed by Western-blot using Odyssey imaging systems (LI-COR
Biosciences, USA). geOMVs preparations digested with proteinase K were analyzed using 1:500 dilutions of the
mouse sera.
Whole cell ELISAs. S. pneumoniae (serotype 9 V and 14, Statens Serum Institut, Denmark) was grown overnight on blood agar plates at 37 °C with 5% CO2 aerobic conditions. The next day the cells were scraped from the
agar plate, resuspended in 1× PBS, and heat inactivated by incubation at 60 °C for 2 h. The cells were diluted to
OD600 ~ 0.6/mL in PBS with protease inhibitor and 100 μ L were seeded into ELISA 96 well plates. The plates were
incubated overnight at 4 °C. The following day, the wells were washed three times with 1× PBS before blocking
with 2.5% skim milk for 2 h. The wells were washed three times with PBS and incubated with 100 μ L of mouse sera
(1:500 dilution) was added to each well and the plates were incubated at room temperature for 1 h. After incubation, the wells were washed again three times with PBS and 100 μ L of IgG anti-mouse-alkaline phosphatase antibody was added to each well and incubated at room temperature for 1 h. After the secondary antibody incubation,
Scientific Reports | 6:24931 | DOI: 10.1038/srep24931
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the wells were washed again three times with PBS and 100 μ L of p-nitrophenyl phosphate was added to each well
and the plates were incubated at 37 °C for 1 h followed by reading the absorbance at 405 nm on a BioTek plate
reader.

™

Opsonophagocytosis Assay (OPA).

Blood collection. Blood was collected by intracardiac puncture
from naïve female mice (Charles River, Wilmington, MA), treated with sodium heparin, then diluted to obtain
6.25 ×  106 leukocytes/mL in RPMI 1640 supplemented with 5% heat-inactivated fetal bovin serum, 10 mM
HEPES, 2 mM L-glutamine and 50 μ M 2-mercaptoethanol. All reagents were from Gibco (Invitrogen, Burlington,
ON, Canada).
Bacterial suspension preparation. Isolated colonies on sheep blood agar plates of S. pneumoniae serotype 14
(Statens Serum Institut, Denmark ) were inoculated in 5 ml of Todd-Hewitt Broth (THB) (Becton Dickinson,
Mississauga, ON, Canada) and incubated for 16 h at 37 °C with 5% CO2. Working cultures were prepared by
transferring 0.1 mL of 16 h-cultures into 10 mL of THB which was incubated for 5 h. Bacteria were washed 3
times and resuspended in PBS to obtain an OD600 value of 0.6, which corresponds to 2 ×  108 colony forming units
(CFU)/mL. Final bacterial suspension was prepared in complete cell culture medium to obtain a concentration
of 6.25 ×  104 CFU/mL. The number of CFU/mL in the final suspension was determined by plating samples onto
Todd-Hewitt Agar (THA) using an Autoplate 4000 Automated Spiral Plater (Spiral Biotech, Norwood, MA).
Assay. Diluted whole blood (5 ×  105 total leukocytes) was mixed with 5 ×  103 CFU of S. pneumoniae (MOI of
0.01) and either 5% or 20% (v/v) of serum from control (placebo) or vaccinated mice in a microtube to a final
volume of 0.2 mL. Microtubes were incubated for 2 h or 4 h at 37 °C with 5% CO2, with shaking. After incubation, viable bacterial counts were performed on THA using an Autoplate 4000 Automated Spiral Plater. Tubes
with addition of naive mouse sera (5% or 20% v/v) or of commercial rabbit anti-S. pneumoniae type 14 serum
(20% v/v) (Statens Serum Institut, Denmark), were used as negative and positive controls, respectively. The % of
bacteria killed was determined using the following formula: % Bacteria killed =  [1 −  (bacteria recovered from
sample tubes/ bacteria recovered from negative control tubes with naïve sera)] ×  100. Final OPA conditions were
selected based in several pre-trials using different incubation times and MOIs (data not shown). A more detailed
procedure can be found in49.
Chicken vaccination and challenge. In general each group contained up to 8 leghorn birds (Poultry Research
Facility, University of Alberta) that were randomly tested for the presence of Campylobacter on the day of hatch
(Day 1) by plating cloacal swabs onto selective Karmali agar. In all cases no Campylobacter colonies were observed
after 48 h of incubation under microaerobic conditions at 37 °C. Vaccination was performed by orally gavaging
with 300 μ L of PBS containing 500 ng of geOMVs on Days 7 and 21. Control groups were gavaged with 300 μ L
of PBS only.
Birds were challenged on day 28 by oral gavaging with either PBS (negative control) or with 300 μ L PBS containing 102 C. jejuni 81–176 cells. The challenge strain was prepared as follows: C. jejuni 81–176 was grown for
18 h on Mueller-Hinton (MH) agar and harvested with cold MH broth. Cells were washed twice with cold PBS
and adjusted to an OD600 of 1.2 (OD600 of 1.2 equals 3 ×  108 cell/mL). Serial dilutions in PBS were performed
dependent on the final amount of cells that were administered. For example: 3 ×  102 cells/mL [ =  1 ×  102 cells
per 300 μ L (= 1 dose)]. Cells were maintained on ice until used. Birds were maintained for an additional 7 days
after challenge and then euthanized. Ceca were removed and the contents were adjusted to 1 mg cecal content per
1 mL with sterile PBS. Aliquots of 10-fold serial dilutions (in PBS) of the cecal contents were plated onto selective
Karmali agar. CFU were determined after incubation of the plates for 48 h under microaerobic conditions.
ELISA for C. jejuni N-glycan-specific antibodies. Blood samples were collected on Day 28 (vaccine response prior
to challenge) and kept at 37 °C until a firm blood clot was formed. Samples were centrifuged (5 min, 18.000 ×  g,
4 °C) and the supernatants (sera) were transferred to fresh tubes. After addition of glycerol to a final concentration of 10%, sera were stored at − 20 °C until further use. For ELISA coating, Campylobacter N-glycan compounds (Cj-N-glycan) and their chemical conjugation to the protein carrier bovine serum albumin (BSA) was
performed as described50,51. Maxisorb plates (Thermo Fisher) were coated with 500 ng of BSA-Cj-N-glycan conjugate per well for 18 h at 4 °C. After removal of unbound antigen the plate was blocked for 1 h at room temperature
with PBS-Tween, 5% skim milk. After discarding the blocking solution 100 μ L of chicken sera diluted 1:10 in
PBS-Tween, 1% skim milk was added to each well. Plates were incubated for 1 h at room temperature and washed
3 times for 5 min with PBS-Tween. After addition of 100 μ L of 2nd antibody solution (anti chicken IgY, diluted
1:500 in PBS-Tween, 1% skim milk) and incubation for 1 h at room temperature wells were washed 4-times for
5 min with 100 μ L of PBS-Tween and developed using the 1-Step p-Nitrophenyl Phosphate (PNPP) assay following the instructions of the manufacturer (Thermo Fisher). Immuno-reactivity in each serum was determined after
reading the plate at OD405 in a plate reader.
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